Mesenchymal Stem Cells –

Mesenchymal Stem Cells – Advances & Applications”

(anybody read this report or owns it in book form ?)v





Global Strategic Report
250 Pages; November 2015

Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, and potentially, other cell types. For years it has been clear that MSCs are a leading type of stem cell being investigated for therapeutic applications, because they have the potential to treat a wide range of acute and degenerative diseases.
In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic.
MSCs are also advantageous over other stem cells types, because they avoid the ethical issues that surround embryonic stem cell research and appear to be immuno-privileged. Importantly, MSCs also well-suited for use in the exponential growth area of 3D printing, because of their unusual capacity to form structural tissues.
To date, there have been more than 30,000 scientific publications published about the cell type and there are now nearly 500 MSC clinical trials underway worldwide, with East Asia, Europe, and the United States representing hot-spots for clinical trial activity.
Furthermore, mesenchymal stem cells surpassed hematopoietic stem cells to become themost common stem cell type to appear within the scientific literature in 2015. MSCs were also the only stem cell type that had an increase in scientific publications from 2014 to 2015.
Google Trend data also shows MSC searches to be approximately twice as common as the next most common adult stem cell type.
Therefore, this global strategic report describes the current status of MSC research, ongoing clinical trials involving MSCs, late stage MSC clinical trials, and possible uses of MSCs in cell therapy. Because MSCs are a sub-segment of the broader cell therapy (CT) and regenerative medicine (RM) markets, it gives an overview of the regenerative medicine industry and overall cell therapy industry.
It also explores recent advances in MSC products and technologies, identifies research priorities by market segment, and assesses 35 leading competitors within the MSC marketplace.
For pharmaceutical companies, it reveals how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies.
The mesenchymal stem cell market is important because:
1) Mesenchymal stem cells (MSCs) are one of the fastest growing areas of stem cell research
2) MSCs are now more frequently cited than any other stem cell type within the scientific literature
3) Google Trend data shows MSC searches to be approximately twice as common as the next most common adult stem cell type
The main objectives of the report are to consider the following:
– Current status of global regenerative medicine (RM) industry in the utilization of stem cells in general and MSCs in particular
– Current status of global cell therapy (CT) industry, the application of cell therapy in various disease indications, and the total number of clinical trials involving the different types of stem cells
– Current status of MSCs in clinical trials,
the dominance of MSCs in the ongoing clinical trials involving stem cells, the various applications of MSCs in different disease indications, and the number of clinical trials involving MSCs for different disease types
– The number of companies involved in the development of MSCs, the clinical trials sponsored by major companies, and their ongoing search for MSCs-based cell therapy products
– Analysis of traditional market metrics (grant rates, clinical trial rates, patent rates, scientific publication rates) and new social analytics (metrics from social media sites, search engines, Google Trends, and more)
Key questions answered in the report are:
– How many companies are currently supporting the regenerative medicine (RM) industry?
– What is the current regional breakdown of RM industry?
– How many RM products have been approved?
– What are the types of diseases are currently being pursued by RM companies?
– What are the major financial events, partnerships and acquisitions in RM sector?
– How do the large pharma companies perceive the value and long-term prospects of RM and cell therapy (CT)?
– What are the major anticipated RM clinical events in 2015-16?
– What are the major therapeutic opportunities for the big pharma in RM and CT?
– How many CT product candidates have reached the Phase III stage and what are they?
– What are the CT product candidates being developed for cardiovascular diseases, central nervous system, wounds, spine and orthopedics, diabetes and autoimmune diseases?
– What are the major commercially available CT products?
– What is the total number of CT clinical trials at the global level?
– What are the major cell types used in CT clinical trials?
– What are the major indications addressed by CT clinical trials?
– What are the major CT clinical trials that have reached Phase III?
– How many CT clinical trials failed in the past year and what are they?
– What are the contributions of MSCs to the cell therapy industry?
– What are the biological properties of MSCs?
– What do MSCs get differentiated into?
– What bioactive molecules do the MSCs secrete?
– What are the immunomodulatory functions of MSCs?
– What are the factors impacting the acquisition of MSCs?
– What are the various sources of MSCs?
– What are the ongoing clinical trials using bone marrow-derived MSCs (BMMSCs) for kidney diseases?
– What are the major clinical trials focusing on diabetes using BMMSCs?
– What are the major clinical trials involving BMMSCs for cardiovascular diseases?
– What are the major clinical trials focusing on liver diseases by BMMSCs?
– What are the brain-related diseases addressed by clinical trials using BMMSCs?
– How many clinical trials are conducted for intestinal diseases using MSCs?
– What are the details of clinical trials conducted for musculoskeletal diseases using MSCs?
– Number of clinical trials using MSCs derived from Wharton’s jelly for various diseases?
– What are the disease indications addressed by umbilical cord blood-derived MSCs (UCBMSCs) in current clinical trials?
– What is the current number of clinical trials using MSCs?
– How many major clinical trials using MSCs have reached the Phase III?
– What are the MSCs-based cell therapy products available in the market?
– What is the current size of the MSC marketplace? ...............